Lymphangioleiomyomatosis: Searching for potential biomarkers

Area of Science:

• Biomarker discovery and validation
• Pulmonary medicine
• Extracellular matrix remodeling

Background:

• Lymphangioleiomyomatosis (LAM) diagnosis often requires lung biopsy.
• Current biomarkers, like Vascular Endothelial Growth Factor-D (VEGF-D), have limitations.
• There is a critical need for improved diagnostic biomarkers for LAM.

Purpose of the Study:

• To evaluate the diagnostic accuracy of various serum biomarkers for LAM.
• To compare the diagnostic performance of VEGF-D and matrix metalloproteinase-2 (MMP-2).
• To assess the combined diagnostic utility of VEGF-D and MMP-2.

Main Methods:

• Serum samples from 97 subjects (59 LAM patients, 18 other cystic lung disease patients, 20 healthy controls) were analyzed.
• Thirteen analytes related to extracellular matrix remodeling, lymphatic involvement, and angiogenesis were assessed.
• A scoring method combining VEGF-D and MMP-2 was developed to evaluate diagnostic performance.

Main Results:

• Matrix metalloproteinase-2 (MMP-2) was the only biomarker that differentiated LAM patients from other groups.
• Serum MMP-2 levels were significantly higher in LAM patients compared to controls (p < 0.0001).
• A composite score combining VEGF-D and MMP-2 demonstrated higher diagnostic accuracy (AUC 0.88) than either biomarker alone (VEGF-D AUC 0.815, MMP-2 AUC 0.785).

Conclusions:

• Matrix metalloproteinase-2 (MMP-2) shows promise as a diagnostic biomarker for LAM.
• Combining MMP-2 with VEGF-D significantly enhances diagnostic accuracy for LAM.
• This combined approach may reduce the reliance on invasive lung biopsies for LAM diagnosis.